Log In
BCIQ
Print this Print this
 

REM-1086

  Manage Alerts
Collapse Summary General Information
Company Rel-MD Inc.
DescriptionIntravenous formulation of small molecule inhibitor of family of five Rel transcription factors RELB, C-REL, RELA(p65), NFKB1 and NFKB2
Molecular Target v-rel reticuloendotheliosis viral oncogene homolog A (RELA) (p65) ; v-rel reticuloendotheliosis viral oncogene homolog B (RELB)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today